Cell and tumor genetics of mitotic arrest checkpoints
有丝分裂停滞检查点的细胞和肿瘤遗传学
基本信息
- 批准号:7054702
- 负责人:
- 金额:$ 31.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-02-01 至 2006-10-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The accurate transmission of genetic information during the cell cycle is dependent on the correct operation of a spindle assembly checkpoint the monitors the state of chromosome-microtubule attachment. Signals generated at kinetochores and transmitted via a transduction system comprised of Mad and Bub proteins, act to regulate the activity of the anaphase promoting complex (APC) thereby linking cell cycle progression to the correct execution of the mechanical events of mitosis. The goal of this work is to probe the mechanisms of checkpoint gene activation with the goal of defining the upstream events that initiate checkpoint signaling and the downstream events that control APC. In addition, the role played by checkpoint lesions in genomic instability in mice will be examined through the use of conditional alleles in two checkpoint genes. Specifically:
(1) The mechanism by which p53-loss rescues the viability of cells lacking a spindle checkpoint will be analyzed in vitro and in vivo
(2) The mechanism of action of a recently discovered negative regulator of Mad2 (CMT2) will be analyzed in detail to uncover key aspects of Mad2-mediated checkpoint signaling.
(3) The proteins responsible for recruiting Mad and Bub proteins to kinetochores will be studied, with particular emphasis on the members of the Ndc80 complex
(4) Bub1, a kinase with dual functions in checkpoint control and chromosome-microtubule attachment will be analyzed using specific mutations that abrogate various functions
(5) The potential role of checkpoint lesions in generating chromosome instability and in promoting cancer will be examined in mice using conditional alleles and mouse model off lung cancer development.
The molecular analysis of checkpoints will have an impact on two aspects of cancer biology. First, it should help to reveal the mechanism off action of important anti-microtubule chemotherapeutics such as taxol and the vinca alkaloids. These compounds provoke the spindle checkpoint, and lesions in the checkpoint are very likely to alter the effectiveness of these drugs in the clinic. Second, careful study of the spindle checkpoint should clarify the role of chromosome instability on tumor development.
描述(由申请人提供):细胞周期中遗传信息的准确传输取决于主轴组件检查站的正确操作,监测染色体 - 微管附件状态。在动力学上产生的信号,并通过由MAD和BUB蛋白组成的转导系统传输,作用于调节后期促进复合物(APC)的活性,从而将细胞周期的进程与有丝分裂的机械事件的正确执行联系起来。这项工作的目的是探测检查点基因激活的机制,目的是定义启动检查点信号传导和控制APC的下游事件的上游事件。此外,检查点病变在小鼠基因组不稳定性中所起的作用将通过在两个检查点基因中使用条件等位基因来检查。具体来说:
(1)将在体外和体内分析缺乏主轴检查点的细胞的可行性的机制
(2)将详细分析最近发现的MAD2负面调节剂(CMT2)的作用机理,以发现MAD2介导的检查点信号的关键方面。
(3)将研究负责招募MAD和BUB蛋白到动物学的蛋白质,特别强调NDC80复合体的成员
(4)BUB1,将使用特定的突变分析检查点控制和染色体 - 微管附着的双重功能的激酶,以消除各种功能
(5)检查点病变在产生染色体不稳定性和促进癌症方面的潜在作用将在小鼠中使用条件等位基因和肺癌发展中的小鼠模型检查。
检查点的分子分析将对癌症生物学的两个方面产生影响。首先,它应该有助于揭示重要的抗微管化学治疗剂(例如紫杉醇和VINCA生物碱)的作用的机制。这些化合物引起了主轴检查点,检查点中的病变很可能会改变诊所中这些药物的有效性。其次,对主轴检查点的仔细研究应阐明染色体不稳定性在肿瘤发育中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
PETER Karl SORGER的其他基金
Pre-cancer atlases of cutaneous and hematologic origin (PATCH Center)
皮肤和血液来源的癌前图谱(PATCH 中心)
- 批准号:1081880310818803
- 财政年份:2023
- 资助金额:$ 31.55万$ 31.55万
- 项目类别:
Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs
免疫检查点和小分子药物治疗和不良反应的系统药理学
- 批准号:1040581210405812
- 财政年份:2021
- 资助金额:$ 31.55万$ 31.55万
- 项目类别:
Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs
免疫检查点和小分子药物治疗和不良反应的系统药理学
- 批准号:1034383510343835
- 财政年份:2018
- 资助金额:$ 31.55万$ 31.55万
- 项目类别:
Project 1: Multi-scale modeling of adaptive drug resistance in BRAF-mutant melanoma
项目 1:BRAF 突变黑色素瘤适应性耐药的多尺度建模
- 批准号:1034383910343839
- 财政年份:2018
- 资助金额:$ 31.55万$ 31.55万
- 项目类别:
Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs
免疫检查点和小分子药物治疗和不良反应的系统药理学
- 批准号:98862119886211
- 财政年份:2018
- 资助金额:$ 31.55万$ 31.55万
- 项目类别:
Pharmaco Response Signatures and Disease Mechanism
药物反应特征和疾病机制
- 批准号:89262398926239
- 财政年份:2014
- 资助金额:$ 31.55万$ 31.55万
- 项目类别:
相似国自然基金
长链非编码RNA LncLsm3a通过调控NS1蛋白干扰素拮抗功能促进A型流感病毒感染和复制的分子机制
- 批准号:32302957
- 批准年份:2023
- 资助金额:20 万元
- 项目类别:青年科学基金项目
RNA结合E3泛素连接酶DZIP3结合炎症因子和I型干扰素mRNA并转录后水平抑制其产生的机制研究
- 批准号:32300725
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
外泌体-小干扰RNA体系的构建及其调控肿瘤微环境的机制与应用研究
- 批准号:32371448
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
RNA干扰和白细胞介素-2联合治疗慢性乙型肝炎的效应和机制研究
- 批准号:82302505
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
长链非编码RNA AATBC结合并干扰SRSFs蛋白发生相分离调控RNA可变剪接促进三阴性乳腺癌耐药的机制研究
- 批准号:82273174
- 批准年份:2022
- 资助金额:52.00 万元
- 项目类别:面上项目
相似海外基金
Mechanisms of Genomic Stability by Mammalian Argonaute Proteins
哺乳动物 Argonaute 蛋白的基因组稳定性机制
- 批准号:1028098310280983
- 财政年份:2021
- 资助金额:$ 31.55万$ 31.55万
- 项目类别:
Mechanisms of Genomic Stability by Mammalian Argonaute Proteins
哺乳动物 Argonaute 蛋白的基因组稳定性机制
- 批准号:1047192210471922
- 财政年份:2021
- 资助金额:$ 31.55万$ 31.55万
- 项目类别:
Mechanisms of Genomic Stability by Mammalian Argonaute Proteins
哺乳动物 Argonaute 蛋白的基因组稳定性机制
- 批准号:1064624510646245
- 财政年份:2021
- 资助金额:$ 31.55万$ 31.55万
- 项目类别:
Molecular mechanisms of germline DNA repair and DNA damage response
种系DNA修复和DNA损伤反应的分子机制
- 批准号:88922088892208
- 财政年份:2014
- 资助金额:$ 31.55万$ 31.55万
- 项目类别:
Molecular mechanisms of germline DNA repair and DNA damage response
种系DNA修复和DNA损伤反应的分子机制
- 批准号:92290569229056
- 财政年份:2014
- 资助金额:$ 31.55万$ 31.55万
- 项目类别: